153
Participants
Start Date
June 3, 2020
Primary Completion Date
June 30, 2029
Study Completion Date
June 30, 2029
AUTO1
Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
Memorial Sloan Kettering Cancer Center, New York
University of Rochester, Rochester
University of Maryland Medical Center, Baltimore
Winship Cancer Institute of Emory University, Atlanta
University of Miami, Miami
H Lee Moffitt Cancer Center, Tampa
TriStar Centennial Medical Center (SCRI), Nashville
Hospital Universitario Virgen del Rocío, Seville
Cleveland Clinic, Cleveland
Hospital Universitario La Fé, Valencia
The Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
University of Chicago, Chicago
Washington University School of Medicine, St Louis
University of Kansas, Kansas City
University of Nebraska, Omaha
Baylor Scott & White Research Institute, Dallas
MD Anderson Cancer Center, Houston
TTI-Methodist (Texas Transplant Institute) (SCRI), San Antonio
Colorado Blood Cancer Institute (CBCI), Denver
University of California San Diego Health (UCSD), La Jolla
City of Hope National Medical Center, Duarte
University of California San Francisco (UCSF), San Francisco
University of California Davis (UC Davis), Sacramento
Dana-Farber Cancer Institute, Boston
Fundacio' Hospital Universitari Vall d'Hebron, Barcelona
Cambridge University Hospitals NHS Foundation Trust, Cambridge
University College London Hospitals NHS Foundation Trust, London
King's College Hospital, London
Manchester Royal Infirmary Hospital, Manchester
Queen Elizabeth University Hospital, Glasgow
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
University Hospitals Birmingham NHS Foundation Trust, Birmingham
University Hospitals Bristol and Weston NHS Foundation Trust (UHBW), Bristol
Autolus Limited
INDUSTRY